IOBTQ · IO Biotech, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has concluded that the aforementioned conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued and therefore, the Company may not be able to continue its currently ongoing research and development activities as planned and realize its assets and satisfy its liabilities in the normal course of business.”View the 10-Q filed Nov 14, 2025
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-06-05 | Hunter Heidi |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
35,144 |
| 2025-06-05 | Elling Christian E |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
35,144 |
| 2025-06-05 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
35,144 |
| 2025-06-05 | Smith David V |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
35,144 |
| 2025-06-05 | Collins Helen Louise |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
35,144 |
| 2025-06-05 | Glaub Kathleen Sereda |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
35,144 |
| 2025-05-30 | Hunter Heidi |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The transaction was executed in multiple trades in prices ranging from $1.37 to $1.40, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
15,000 |
| 2025-04-02 | Zocca Mai-Britt |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
580,000 |
| 2025-04-02 | Burkavage Brian |
Controller |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
65,000 |
| 2025-04-02 | Ahmad Qasim Iftikhar |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
215,000 |
| 2025-04-02 | Sullivan Amy |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
215,000 |
| 2025-04-02 | Smith Devin Whittemore |
SVP and General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
140,000 |
| 2024-12-23 | Sullivan Amy |
Chief Financial Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The transaction was executed in multiple trades in prices ranging from $0.7861 to $0.90, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
10,250 |
| 2024-12-23 | Smith Devin Whittemore |
SVP and General Counsel |
Buy↑
|
Common Stock
|
12,000 |
| 2024-12-23 | Zocca Mai-Britt |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The actual purchase price is $0.809556 per share of Common Stock, which has been rounded due to systematic character limitations. |
Common Stock
|
12,500 |
| 2024-12-23 | Ahmad Qasim Iftikhar |
Chief Medical Officer |
Buy↑
|
Common Stock
|
31,350 |
| 2024-07-26 | Novo Holdings A/S |
10% Owner |
Sell↓
Filing footnotes — COMMON STOCK (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
COMMON STOCK
|
23,478 |
| 2024-07-25 | Novo Holdings A/S |
10% Owner |
Sell↓
Filing footnotes — COMMON STOCK (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
COMMON STOCK
|
51,522 |
| 2024-06-06 | Smith David V |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
45,642 |
| 2024-06-06 | Elling Christian E |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
45,642 |
| 2024-06-06 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
45,642 |
| 2024-06-06 | Collins Helen Louise |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
45,642 |
| 2024-06-06 | Hunter Heidi |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
45,642 |
| 2024-06-06 | Glaub Kathleen Sereda |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
45,642 |
| 2024-05-10 | Novo Holdings A/S |
10% Owner |
Sell↓
|
COMMON STOCK
|
658,809 |
| 2024-03-15 | Smith Devin Whittemore |
SVP and General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
185,000 |
| 2024-03-15 | Ahmad Qasim Iftikhar |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
280,000 |
| 2024-03-15 | Zocca Mai-Britt |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
750,000 |
| 2024-03-15 | Sullivan Amy |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
280,000 |
| 2024-03-15 | Burkavage Brian |
Controller |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Stock Option (Right to Buy)
|
50,000 |
| 2024-02-09 | Novo Holdings A/S |
10% Owner |
Sell↓
Filing footnotes — COMMON STOCK (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
COMMON STOCK
|
658,809 |
| 2023-11-22 | Burkavage Brian |
Controller |
Buy↑
Filing footnotes — Common Stock (Direct)
The transaction was executed in multiple trades in prices ranging from $1.03 to $1.04, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. |
Common Stock
|
5,000 |
| 2023-11-21 | Burkavage Brian |
Controller |
Buy↑
|
Common Stock
|
5,000 |
| 2023-11-15 | Collins Helen Louise |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
64,238 |
| 2023-11-09 | Collins Helen Louise |
CHIEF MEDICAL OFFICER |
Other↑
|
No Securities Owned
|
0 |
| 2023-08-11 | Hunter Heidi |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control. |
Stock Option (Right to Buy)
|
64,238 |
| 2023-08-11 | Hunter Heidi |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2023-08-09 | Lundbeckfond Invest A/S |
10% Owner |
Award↑
Filing footnotes — Warrants (Right to Buy) (Direct)
These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023). |
Warrants (Right to Buy)
|
7,901,234 |
| 2023-08-09 | Sullivan Amy |
Chief Financial Officer |
Award↑
Filing footnotes — Warrants (Right to Buy) (Direct)
These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023. |
Warrants (Right to Buy)
|
49,382 |
| 2023-08-09 | Novo Holdings A/S |
10% Owner |
Buy↑
Filing footnotes — Common Stock Warrant (Right to Buy) (Direct)
Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement. |
Common Stock Warrant (Right to Buy)
|
2,469,135 |
| 2023-08-09 | Zocca Mai-Britt |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Warrants (Right to Buy) (Direct)
These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023. |
Warrants (Right to Buy)
|
37,037 |
| 2023-08-09 | Zocca Mai-Britt |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
37,037 |
| 2023-08-09 | Vivo Capital IX, LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
Purchase was made pursuant to that certain Securities Purchase Agreement dated as of August 7, 2023, by and among the Issuer and the purchasers named therein. The securities are held directly by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As the managing members of Vivo Opportunity, LLC, Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P., but each disclaims beneficial ownership of such securities except to the extent of their individual pecuniary interest therein. |
Common Stock
(I)
|
3,157,894 |
| 2023-08-09 | Smith Devin Whittemore |
SVP and General Counsel |
Award↑
|
Common Stock
|
4,938 |
| 2023-08-09 | Smith Devin Whittemore |
SVP and General Counsel |
Award↑
Filing footnotes — Warrants (Right to Buy) (Direct)
These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023. |
Warrants (Right to Buy)
|
4,938 |
| 2023-08-09 | Novo Holdings A/S |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement. |
Common Stock
|
2,469,135 |
| 2023-08-09 | Elling Christian E |
Director |
Award↑
Filing footnotes — Common Stock (Indirect)
The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any. |
Common Stock
(I)
|
7,901,234 |
| 2023-08-09 | Lundbeckfond Invest A/S |
10% Owner |
Award↑
|
Common Stock
|
7,901,234 |
| 2023-08-09 | Elling Christian E |
Director |
Award↑
Filing footnotes — Warrants (Right to Buy) (Indirect)
These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023). The securities are held of record by Lundbeckfond Invest A/S. The Reporting Person is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. The Reporting Person disclaims beneficial ownership of the securities held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein, if any. |
Warrants (Right to Buy)
(I)
|
7,901,234 |
| 2023-08-09 | Sullivan Amy |
Chief Financial Officer |
Award↑
|
Common Stock
|
49,382 |